Pharmaceuticals, Biotechnology and Life Sciences
V-Bio Ventures has announced the final closing of its second fund, V-Bio Fund 2, having raised EUR 110 million euro and exceeding its target of EUR 100 million.
V-Bio Ventures has announced the completion of a EUR 80m Series B round of it’s portfolio company Precirix NV led by new investors INKEF Capital, Jeito Capital and Forbion as co-leads.
V-Bio Ventures has announced the completion the acquisition of its portfolio company Syndesi Therapeutics SA by AbbVie (NYSE: ABBV), which…